Compare CUBI & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CUBI | SLS |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2010 | 2007 |
| Metric | CUBI | SLS |
|---|---|---|
| Price | $80.76 | $13.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $85.00 | $10.00 |
| AVG Volume (30 Days) | 190.9K | ★ 6.7M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.99 | ★ 50.00 |
| EPS | ★ 4.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.95 | N/A |
| Revenue Next Year | $9.50 | $110.98 |
| P/E Ratio | $19.71 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $59.34 | $1.39 |
| 52 Week High | $84.38 | $15.88 |
| Indicator | CUBI | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 53.11 |
| Support Level | $72.04 | $11.43 |
| Resistance Level | $79.38 | $15.77 |
| Average True Range (ATR) | 1.79 | 1.24 |
| MACD | -0.31 | -0.06 |
| Stochastic Oscillator | 40.27 | 36.45 |
Customers Bancorp Inc is a bank holding company conducting banking activities through its wholly owned subsidiary, Customers Bank. The Bank provides commercial and consumer customers the stability of a regulated financial institution supported by risk management. It serves commercial and corporate businesses nationwide, including healthcare, real estate, specialty finance, fund finance, technology and venture capital banking, mortgage finance and commercial equipment financing, and provides payments and treasury services. The Bank also serves consumers through its branch network, offering residential mortgages and personal loan and deposit products, including Banking-as-a-Service, with services delivered predominantly in Southeastern and Central Pennsylvania, New York, and other states.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.